Tak CR, et al. - In order to evaluate the cost-effectiveness of a cancer surveillance strategy for patients with Li–Fraumeni syndrome [LFS] vs those whose tumors present clinically, researchers developed a Markov decision analytic model from a third-party payer perspective. The model consisted of four possible health conditions: no cancer, cancer, post-cancer survivorship, and death. According to the findings, the model exhibited a mean cost of $46 496 and $117 102 and yielded 23 and 27 life years [LY] for the nonsurveillance and surveillance strategies. Presymptomatic cancer surveillance in patients with germline pathogenic variants in TP53 is cost-effective. Lack of insurance coverage or reimbursement in this population can have significant consequences and lead to undetected cancers with worse clinical results in later stages of the disease.